Rankings
▼
Calendar
ALNY FY 2019 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$42B
FY 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$220M
+193.4% YoY
Gross Profit
$195M
88.6% margin
Operating Income
-$939M
-427.5% margin
Net Income
-$886M
-403.2% margin
EPS (Diluted)
$-8.11
Cash Flow
Operating Cash Flow
-$278M
Free Cash Flow
-$419M
Stock-Based Comp.
$175M
Balance Sheet
Total Assets
$2.4B
Total Liabilities
$956M
Stockholders' Equity
$1.4B
Cash & Equivalents
$547M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$220M
$75M
+193.4%
Gross Profit
$195M
$73M
+166.3%
Operating Income
-$939M
-$815M
-15.3%
Net Income
-$886M
-$761M
-16.4%
← Q4 2018
All Quarters
Q1 2019 →